Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 34.6% in May

Aprea Therapeutics, Inc. (NASDAQ:APREGet Free Report) was the target of a significant decrease in short interest in May. As of May 31st, there was short interest totalling 21,200 shares, a decrease of 34.6% from the May 15th total of 32,400 shares. Based on an average daily trading volume, of 29,200 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.4% of the shares of the stock are sold short.

Analysts Set New Price Targets

Several research firms have weighed in on APRE. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a research note on Tuesday, May 14th. Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Aprea Therapeutics in a research note on Tuesday, May 14th.

View Our Latest Report on Aprea Therapeutics

Aprea Therapeutics Stock Performance

NASDAQ APRE opened at $4.41 on Friday. The business has a fifty day moving average price of $5.20 and a two-hundred day moving average price of $5.47. Aprea Therapeutics has a fifty-two week low of $2.78 and a fifty-two week high of $8.85.

Aprea Therapeutics (NASDAQ:APREGet Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.11. Aprea Therapeutics had a negative return on equity of 56.78% and a negative net margin of 1,317.82%. The company had revenue of $0.38 million during the quarter. As a group, research analysts predict that Aprea Therapeutics will post -2.57 EPS for the current fiscal year.

About Aprea Therapeutics

(Get Free Report)

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.

Further Reading

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.